Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-301
- Development stage
- Unknown
- Lead developer
- Eluminex
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Ophthalmic
01
Overview
EB-301 is a novel, clinical-stage, recombinant human collagen type III (rhCIII) biosynthetic cornea being developed to address corneal blindness and visual acuity deficits caused by stable, non-infectious stromal lesions. It is an acellular, engineered collagen implant designed to replace or reinforce diseased corneal stroma and restore corneal clarity, thereby improving visual acuity, while reducing dependence on human donor corneas and mitigating risks associated with allograft transplantation.[10][11][12]
- Other names
- rhCIII biosynthetic cornearecombinant human collagen type III biosynthetic cornea
Beyond the preview
Go deeper on EB-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-301.